172 related articles for article (PubMed ID: 31367891)
1. [Imaging of medullary thyroid carcinoma].
Uhrig M; Delorme S
Radiologe; 2019 Nov; 59(11):992-1001. PubMed ID: 31367891
[TBL] [Abstract][Full Text] [Related]
2. Medullary Thyroid Carcinoma: Imaging.
Delorme S; Raue F
Recent Results Cancer Res; 2015; 204():91-116. PubMed ID: 26494385
[TBL] [Abstract][Full Text] [Related]
3. Anti-carcinoembryonic antigen antibodies versus somatostatin analogs in the detection of metastatic medullary thyroid carcinoma: are carcinoembryonic antigen and somatostatin receptor expression prognostic factors?
Behr TM; Gratz S; Markus PM; Dunn RM; Hüfner M; Schauer A; Fischer M; Munz DL; Becker H; Becker W
Cancer; 1997 Dec; 80(12 Suppl):2436-57. PubMed ID: 9406695
[TBL] [Abstract][Full Text] [Related]
4. Positron emission tomography (18FDG-PET) in the detection of medullary thyroid carcinoma metastases.
Mucha SA; Kunert-Radek J; Pomorski L
Endokrynol Pol; 2006; 57(4):452-5. PubMed ID: 17006852
[TBL] [Abstract][Full Text] [Related]
5. Gallium-68 Dotatate PET/CT is superior to other imaging modalities in the detection of medullary carcinoma of the thyroid in the presence of high serum calcitonin.
Tran K; Khan S; Taghizadehasl M; Palazzo F; Frilling A; Todd JF; Al-Nahhas A
Hell J Nucl Med; 2015; 18(1):19-24. PubMed ID: 25679074
[TBL] [Abstract][Full Text] [Related]
6. Complementary roles of 18F-DOPA PET/CT and 18F-FDG PET/CT in medullary thyroid cancer.
Kauhanen S; Schalin-Jäntti C; Seppänen M; Kajander S; Virtanen S; Schildt J; Lisinen I; Ahonen A; Heiskanen I; Väisänen M; Arola J; Korsoff P; Ebeling T; Sane T; Minn H; Välimäki MJ; Nuutila P
J Nucl Med; 2011 Dec; 52(12):1855-63. PubMed ID: 22052128
[TBL] [Abstract][Full Text] [Related]
7. High CEA levels in a case of resected colorectal cancer: delayed diagnosis of metachronous medullary thyroid cancer.
Chen SW; Chen YK
World J Surg Oncol; 2017 Dec; 15(1):230. PubMed ID: 29284496
[TBL] [Abstract][Full Text] [Related]
8. Prospective study on the clinical relevance of
Califano I; Pitoia F; Chirico R; De Salazar A; Bastianello MJ
Endocrine; 2022 Jun; 77(1):143-150. PubMed ID: 35489000
[TBL] [Abstract][Full Text] [Related]
9. Impact of ¹⁸F-FDG PET/CT for detecting recurrence of medullary thyroid carcinoma.
Ozkan E; Soydal C; Kucuk ON; Ibis E; Erbay G
Nucl Med Commun; 2011 Dec; 32(12):1162-8. PubMed ID: 21946617
[TBL] [Abstract][Full Text] [Related]
10. Medullary Thyroid Carcinoma: Do Ultrasonography and F-DOPA-PET-CT Influence the Initial Surgical Strategy?
Brammen L; Niederle MB; Riss P; Scheuba C; Selberherr A; Karanikas G; Bodner G; Koperek O; Niederle B
Ann Surg Oncol; 2018 Dec; 25(13):3919-3927. PubMed ID: 30306375
[TBL] [Abstract][Full Text] [Related]
11. Relevance of calcitonin cut-off in the follow-up of medullary thyroid carcinoma for conventional imaging and 18-fluorine-fluorodihydroxyphenylalanine PET.
Sesti A; Mayerhoefer M; Weber M; Anner P; Wadsak W; Dudczak R; Haug A; Karanikas G
Anticancer Res; 2014 Nov; 34(11):6647-54. PubMed ID: 25368270
[TBL] [Abstract][Full Text] [Related]
12. Clinical value of 18-fluorine-fluorodihydroxyphenylalanine positron emission tomography/computed tomography in the follow-up of medullary thyroid carcinoma.
Luster M; Karges W; Zeich K; Pauls S; Verburg FA; Dralle H; Glatting G; Buck AK; Solbach C; Neumaier B; Reske SN; Mottaghy FM
Thyroid; 2010 May; 20(5):527-33. PubMed ID: 20450432
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic utility of PET/CT with
Romero-Lluch AR; Cuenca-Cuenca JI; Guerrero-Vázquez R; Martínez-Ortega AJ; Tirado-Hospital JL; Borrego-Dorado I; Navarro-González E
Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):2004-2013. PubMed ID: 28646462
[TBL] [Abstract][Full Text] [Related]
14. Management of thyroid cancer: United Kingdom National Multidisciplinary Guidelines.
Mitchell AL; Gandhi A; Scott-Coombes D; Perros P
J Laryngol Otol; 2016 May; 130(S2):S150-S160. PubMed ID: 27841128
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic Challenges of Medullary Thyroid Carcinoma.
Leimbach RD; Hoang TD; Shakir MKM
Oncology; 2021; 99(7):422-432. PubMed ID: 33878761
[TBL] [Abstract][Full Text] [Related]
16. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Follow-up in Medullary Thyroid Carcinoma.
Raue F; Frank-Raue K
Recent Results Cancer Res; 2015; 204():207-25. PubMed ID: 26494391
[TBL] [Abstract][Full Text] [Related]
18. Predictive and prognostic value of 18F-DOPA PET/CT in patients affected by recurrent medullary carcinoma of the thyroid.
Caobelli F; Chiaravalloti A; Evangelista L; Saladini G; Schillaci O; Vadrucci M; Scalorbi F; Donner D; Alongi P;
Ann Nucl Med; 2018 Jan; 32(1):7-15. PubMed ID: 28986764
[TBL] [Abstract][Full Text] [Related]
19. [
Rasul S; Hartenbach S; Rebhan K; Göllner A; Karanikas G; Mayerhoefer M; Mazal P; Hacker M; Hartenbach M
Eur J Nucl Med Mol Imaging; 2018 Nov; 45(12):2159-2169. PubMed ID: 29766245
[TBL] [Abstract][Full Text] [Related]
20. The value of 18F-DOPA PET/CT in patients with medullary thyroid carcinoma and increased calcitonin values.
Golubić AT; Pasini Nemir E; Žuvić M; Mutvar A; Kusačić Kuna S; Despot M; Samardžić T; Huić D
Nucl Med Commun; 2017 Jul; 38(7):636-641. PubMed ID: 28562377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]